Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 111-120 of 406 for multiple

Edit search filters
  1. A Study Designed To Evaluate The Safety And Efficacy Of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) In Participants With T(11;14)-Positive Relapsed Or Refractory Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  2. Daratumumab Retreatment In Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)

    Rochester, MN

  3. A Phase III, Safety, Tolerability And Efficacy Of Combination Treatment Of BL-8040 And G-GSF As Compared To Placebo And G-CSF For ThE MobilizatioN Of HematopoiEtic Stem Cells For Autologous TransplantatIon In SubjectS With MM

    Rochester, MN

  4. A Study To Assess The Adverse Events And Change In Disease Activity In Adult Participants With Relapsed Or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

    Rochester, MN

  5. A Study To Evaluate VSV-hIFNbeta-NIS To Treat Patients With Relapsed/Refractory Multiple Myleoma, Acute Myeloid Leukemia, Or T-cell Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study Of Daratumumab, Bortezomib, Lenalidomide And Dexamethasone (DVRd) Followed By Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide And Dexamethasone (DVRd) Followed By Autologous Stem Cell Transplant (ASCT) In Participants With Newly Diagnosed Multiple Myeloma

    Rochester, MN

  7. A Study To Evaluate APG2575 Combined With Novel Therapeutic Regimens To Treat Subjects With Relapsed Or Refractory Multiple Myeloma And Immunoglobulin Light Chain Amyloidosis

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  8. A Study to Determine if an Early Alert Checklist Can Help Prevent Severe Organ Damage and Death in Patients with Acute Respiratory Failure

    Rochester, MN

  9. A Study To Assess The Safety And Tolerability Of CFT7455 In Relapsed/Refractory Non-Hodgkin's Lymphoma Or Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

    Jacksonville, FL

.

Mayo Clinic Footer